RGACX
Price
$85.14
Change
-$0.28 (-0.33%)
Updated
Jun 2 closing price
Net Assets
337.53B
VLLIX
Price
$51.22
Change
-$0.89 (-1.71%)
Updated
Jun 2 closing price
Net Assets
468.91M
Interact to see
Advertisement

RGACX vs VLLIX

Header iconRGACX vs VLLIX Comparison
Open Charts RGACX vs VLLIXBanner chart's image
RGACX vs VLLIX Comparison Chart in %
View a ticker or compare two or three
VS
RGACX vs. VLLIX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGACX is a Hold and VLLIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGACX has more cash in the bank: 338B vs. VLLIX (469M). RGACX (0.00) and VLLIX (0.00) have matching dividends . RGACX was incepted earlier than VLLIX: RGACX (24 years) vs VLLIX (11 years). VLLIX (1.22) is less costly to investors than RGACX (0.93). VLLIX is a more actively managed with annual turnover of: 38.00 vs. RGACX (32.00). RGACX has a lower initial minimum investment than VLLIX: RGACX (250) vs VLLIX (100000). VLLIX annual gain was more profitable for investors over the last year : 26.22 vs. RGACX (14.24). VLLIX return over 5 years is better than : 30.60 vs. RGACX (22.53).
RGACXVLLIXRGACX / VLLIX
Total Expense Ratio0.930.88106%
Annual Report Gross Expense Ratio0.931.2276%
Fund Existence24 years11 years-
Gain YTD10.29113.79775%
Front LoadN/AN/A-
Min. Initial Investment2501000000%
Min. Initial Investment IRAN/AN/A-
Net Assets338B469M72,068%
Annual Yield % from dividends0.000.00-
Returns for 1 year14.2426.2254%
Returns for 3 years51.07108.8947%
Returns for 5 years22.5330.6074%
Returns for 10 years107.7997.38111%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TDY618.819.34
+1.53%
Teledyne Technologies
SKLZ10.040.04
+0.40%
Skillz
RAY3.37-0.01
-0.30%
Raytech Holding Limited
ITRI83.84-0.95
-1.12%
Itron
EVMN19.82-2.35
-10.60%
Evommune Inc.